GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B6339 HEAT hydrochlorideSummary: α1-adrenoceptor antagonist -
B6313 Dihydroergocristine mesylateSummary: 5-HT receptor antagonist and partial agonist of adrenergic and dopaminergic receptors -
B5105 SB 204070Summary: Potent and selective 5-HT4 receptor antagonist -
B6303 CimaterolSummary: β-Adrenergic agonist -
B5104 SB 200646 hydrochlorideSummary: 5-HT2C/2B receptor antagonist -
B6022 Metoprolol SuccinateSummary: beta-1 selective adrenergic receptor antagonist -
B5046 Methysergide maleateSummary: Mixed 5-HT1/5-HT2 receptor antagonist -
B5944 Carteolol HClSummary: Non-selective beta-adrenoceptor antagonist -
B5042 RS 39604 hydrochlorideSummary: potent and selective 5-HT4 antagonist -
B5498 RWJ 52353Summary: α2D adrenergic receptor agonist
